分泌物
癌症研究
颗粒酶B
免疫学
体内
颗粒酶
免疫疗法
嵌合抗原受体
表型
白细胞介素21
细胞毒性T细胞
T细胞
肿瘤微环境
细胞生物学
白细胞介素2受体
生物
细胞因子
CD40
癌细胞
体外
癌症免疫疗法
抗原提呈细胞
分子生物学
白细胞介素12
免疫系统
CD8型
穿孔素
内分泌学
生物技术
基因
生物化学
作者
Lintao Liu,Enguang Bi,Xingzhe Ma,Wei Xiong,Jianfei Qian,Lingqun Ye,Pan Su,Qiang Wang,Liuling Xiao,Maojie Yang,Yong Lu,Qing Yi
标识
DOI:10.1038/s41467-020-19672-2
摘要
Abstract CAR-T cell therapy is effective for hematologic malignancies. However, considerable numbers of patients relapse after the treatment, partially due to poor expansion and limited persistence of CAR-T cells in vivo. Here, we demonstrate that human CAR-T cells polarized and expanded under a Th9-culture condition (T9 CAR-T) have an enhanced antitumor activity against established tumors. Compared to IL2-polarized (T1) cells, T9 CAR-T cells secrete IL9 but little IFN-γ, express central memory phenotype and lower levels of exhaustion markers, and display robust proliferative capacity. Consequently, T9 CAR-T cells mediate a greater antitumor activity than T1 CAR-T cells against established hematologic and solid tumors in vivo. After transfer, T9 CAR-T cells migrate effectively to tumors, differentiate to IFN-γ and granzyme-B secreting effector memory T cells but remain as long-lived and hyperproliferative T cells. Our findings are important for the improvement of CAR-T cell-based immunotherapy for human cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI